Overview

Efficacy and Safety of a New Multi-dose Lubricant Eye Drop Concomitant With Restasis® (Cyclosporine A) for the Treatment of Dry Eye Symptoms

Status:
Completed

Trial end date:
2008-01-01

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy, safety and tolerability of a combination of Optive® Artificial Tears with Restasis®.The primary hypothesis is that the Ocular Surface Disease Index (OSDI) score and symptoms will be the same or lower than baseline after treatment in these patients. The patients will tolerate the combination of Restasis® and Optive® with a low incidence of clinical adverse events.

Phase:

Phase 4

Details

Lead Sponsor:

Innovative Medical

Treatments:

Cyclosporine
Cyclosporins
Lubricant Eye Drops
Ophthalmic Solutions